002675 东诚药业
已收盘 05-06 15:00:00
资讯
新帖
简况
东诚药业(002675.SZ):注射用氢化可的松琥珀酸钠通过仿制药一致性评价
智通财经 · 11:52
东诚药业(002675.SZ):注射用氢化可的松琥珀酸钠通过仿制药一致性评价
东诚药业(002675)2025年一季报简析:增收不增利
证券之星 · 04-30
东诚药业(002675)2025年一季报简析:增收不增利
东诚药业(002675)3月31日股东户数2.16万户,较上期减少12.51%
证券之星 · 04-30
东诚药业(002675)3月31日股东户数2.16万户,较上期减少12.51%
东诚药业最新公告:拟3600万元收购控股子公司蓝纳成少数股东股权
证券之星 · 04-29
东诚药业最新公告:拟3600万元收购控股子公司蓝纳成少数股东股权
A股创新药板块震荡走高,华纳药厂涨超10%,热景生物涨超7%,东诚药业、百利天恒、翰宇药业跟涨。
美港电讯 · 04-22
A股创新药板块震荡走高,华纳药厂涨超10%,热景生物涨超7%,东诚药业、百利天恒、翰宇药业跟涨。
【量价齐升榜前十:康鹏科技连续5天放量上涨,累计涨幅27.18%】截至4月15日收盘,康鹏科技量价齐升,连续5天放量上涨,累计涨幅27.18%。其余量价齐升的上涨个股还包括:红宝丽(放量上涨4天)、浙江永强(放量上涨4天)、深康佳A(放量上涨3天)、深圳华强(放量上涨3天)、川润股份(放量上涨3天)、信立泰(放量上涨3天)、大金重工(放量上涨3天)、跨境通(放量上涨3天)、东诚药业(放量上涨3天)。
金融界 · 04-15
【量价齐升榜前十:康鹏科技连续5天放量上涨,累计涨幅27.18%】截至4月15日收盘,康鹏科技量价齐升,连续5天放量上涨,累计涨幅27.18%。其余量价齐升的上涨个股还包括:红宝丽(放量上涨4天)、浙江永强(放量上涨4天)、深康佳A(放量上涨3天)、深圳华强(放量上涨3天)、川润股份(放量上涨3天)、信立泰(放量上涨3天)、大金重工(放量上涨3天)、跨境通(放量上涨3天)、东诚药业(放量上涨3天)。
【创新药概念反复活跃,一品红涨超10%续创历史新高】一品红涨超10%,股价续创历史新高,东诚药业涨停,悦康药业、科兴制药、智翔金泰、前沿生物、热景生物、百济神州等涨幅靠前。
金融界 · 04-14
【创新药概念反复活跃,一品红涨超10%续创历史新高】一品红涨超10%,股价续创历史新高,东诚药业涨停,悦康药业、科兴制药、智翔金泰、前沿生物、热景生物、百济神州等涨幅靠前。
东诚药业:公司在追求经济效益的同时注重环境保护和节能降耗
证券之星 · 03-07
东诚药业:公司在追求经济效益的同时注重环境保护和节能降耗
原料药拖累业绩 东诚药业转向核药
媒体滚动 · 03-06
原料药拖累业绩 东诚药业转向核药
东诚药业:3月5日召开业绩说明会,投资者参与
证券之星 · 03-05
东诚药业:3月5日召开业绩说明会,投资者参与
东诚药业(002675)2024年年报简析:净利润减12.35%
证券之星 · 02-27
东诚药业(002675)2024年年报简析:净利润减12.35%
东诚药业(002675)1月31日股东户数2.47万户,较上期减少2.1%
证券之星 · 02-27
东诚药业(002675)1月31日股东户数2.47万户,较上期减少2.1%
东诚药业:拟使用不超4亿元闲置自有资金购买理财产品
中国财富通 · 02-27
东诚药业:拟使用不超4亿元闲置自有资金购买理财产品
图解东诚药业年报:第四季度单季净利润同比增122.29%
证券之星 · 02-26
图解东诚药业年报:第四季度单季净利润同比增122.29%
东诚药业最新公告:2024年净利同比下降12.35% 拟10派0.3元
证券之星 · 02-26
东诚药业最新公告:2024年净利同比下降12.35% 拟10派0.3元
东诚药业(002675.SZ)发布2024年度业绩,净利润1.84亿元,下降12.35%
智通财经 · 02-26
东诚药业(002675.SZ)发布2024年度业绩,净利润1.84亿元,下降12.35%
东诚药业(002675)2月19日主力资金净卖出748.69万元
证券之星 · 02-20
东诚药业(002675)2月19日主力资金净卖出748.69万元
【投融资动态】蓝纳成生物C轮融资,融资额1.5亿人民币,投资方为瑞力投资、东诚药业等
证券之星 · 02-18
【投融资动态】蓝纳成生物C轮融资,融资额1.5亿人民币,投资方为瑞力投资、东诚药业等
东诚药业(002675.SZ)控股子公司蓝纳成拟实施增资扩股事项 充实资金储备
智通财经 · 02-14
东诚药业(002675.SZ)控股子公司蓝纳成拟实施增资扩股事项 充实资金储备
加载更多
公司概况
公司名称:
烟台东诚药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-05-25
主营业务:
烟台东诚药业集团股份有限公司的主营业务是生化原料药、中西药制剂、放射性核素药物的研发、生产、销售。公司的主要产品是肝素钠原料药、硫酸软骨素、那屈肝素钙注射液、注射用氢化可的松琥珀酸钠、达肝素钠注射液、依诺肝素钠注射液、注射用绒促性素、注射用尿促性素。公司连续七年荣登“中国化药企业TOP100排行榜”,连续四年荣登“中国医药工业百强榜”,连续三年荣获“山东民营企业创新100强”,本年度公司首次荣获“2024中国化药研发实力100强”。
发行价格:
26.00
{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":14.84,"timestamp":1746514980000,"preClose":14.95,"halted":0,"volume":8787200,"delay":0,"changeRate":-0.0074,"floatShares":743000000,"shares":825000000,"eps":0.175,"marketStatus":"已收盘","change":-0.11,"latestTime":"05-06 15:00:00","open":15.04,"high":15.15,"low":14.78,"amount":131000000,"amplitude":0.0247,"askPrice":14.84,"askSize":23,"bidPrice":14.83,"bidSize":258,"shortable":0,"etf":0,"ttmEps":0.175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746581400000},"marketStatusCode":5,"adr":0,"adjPreClose":14.95,"symbolType":"stock","openAndCloseTimeList":[[1746495000000,1746502200000],[1746507600000,1746514800000]],"highLimit":16.45,"lowLimit":13.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.74,"roa":"--","peRate":84.8,"roe":"0.55%","epsLYR":0.2229,"committee":0.649259,"marketValue":12237000000,"turnoverRate":0.0118,"status":1,"floatMarketCap":11032000000},"requestUrl":"/m/hq/s/002675","defaultTab":"news","newsList":[{"id":"2533687311","title":"东诚药业(002675.SZ):注射用氢化可的松琥珀酸钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2533687311","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533687311?lang=zh_cn&edition=full","pubTime":"2025-05-06 19:52","pubTimestamp":1746532327,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东诚药业 发布公告,近日,公司全资子公司烟台东诚北方制药有限公司收到国家药品监督管理局核准签发的关于注射用氢化可的松琥珀酸钠的《药品补充申请批准通知书》,东诚北方生产的注射用氢化可的松琥珀酸钠通过仿制药质量和疗效一致性评价。氢化可的松琥珀酸钠是氢化可的松的盐类化合物,具有抗炎、抗过敏和抑制免疫等多种药理作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2532013556","title":"东诚药业(002675)2025年一季报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2532013556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532013556?lang=zh_cn&edition=full","pubTime":"2025-05-01 06:56","pubTimestamp":1746053772,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期东诚药业发布2025年一季报。根据财报显示,东诚药业增收不增利。截至本报告期末,公司营业总收入6.87亿元,同比上升6.13%,归母净利润2473.15万元,同比下降61.55%。持有东诚药业最多的基金为银河医药混合A,目前规模为4.93亿元,最新净值0.4994,较上一交易日上涨0.5%,近一年上涨0.57%。2025 年在搭建基础工作的过程中,也会有销售收入的增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100005584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2531086413","title":"东诚药业(002675)3月31日股东户数2.16万户,较上期减少12.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531086413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531086413?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:51","pubTimestamp":1746006715,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东诚药业披露,截至2025年3月31日公司股东户数为2.16万户,较1月31日减少3085.0户,减幅为12.51%。在化学制药行业个股中,东诚药业股东户数低于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.2万户。从股价来看,2025年1月31日至2025年3月31日,东诚药业区间涨幅为3.86%,在此期间股东户数减少3085.0户,减幅为12.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000036680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2531659732","title":"东诚药业最新公告:拟3600万元收购控股子公司蓝纳成少数股东股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2531659732","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531659732?lang=zh_cn&edition=full","pubTime":"2025-04-29 21:19","pubTimestamp":1745932773,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称,公司拟以约3600万元人民币收购控股子公司烟台蓝纳成生物技术股份有限公司少数股东深圳景林景盈股权投资基金合伙企业所持1.65%股份。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900042495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2529395377","title":"A股创新药板块震荡走高,华纳药厂涨超10%,热景生物涨超7%,东诚药业、百利天恒、翰宇药业跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529395377","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529395377?lang=zh_cn&edition=full","pubTime":"2025-04-22 10:40","pubTimestamp":1745289614,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688506","300199","BK1574","688068","BK0028","BK0077","159992","BK0070","688799","399300","BK0188","159982","BK1161","BK0239","06978","002675"],"gpt_icon":0},{"id":"2527463328","title":"【量价齐升榜前十:康鹏科技连续5天放量上涨,累计涨幅27.18%】截至4月15日收盘,康鹏科技量价齐升,连续5天放量上涨,累计涨幅27.18%。其余量价齐升的上涨个股还包括:红宝丽(放量上涨4天)、浙江永强(放量上涨4天)、深康佳A(放量上涨3天)、深圳华强(放量上涨3天)、川润股份(放量上涨3天)、信立泰(放量上涨3天)、大金重工(放量上涨3天)、跨境通(放量上涨3天)、东诚药业(放量上涨3天)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527463328","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527463328?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:42","pubTimestamp":1744706548,"startTime":"0","endTime":"0","summary":"截至4月15日收盘,康鹏科技量价齐升,连续5天放量上涨,累计涨幅27.18%。其余量价齐升的上涨个股还包括:红宝丽(放量上涨4天)、浙江永强(放量上涨4天)、深康佳A(放量上涨3天)、深圳华强(放量上涨3天)、川润股份(放量上涨3天)、信立泰(放量上涨3天)、大金重工(放量上涨3天)、跨境通(放量上涨3天)、东诚药业(放量上涨3天)。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/15164249547482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0012","BK0138","BK0050","BK0077","BK0229","000062","BK0172","BK0137","BK0174","002487","BK0107","BK0188","BK0118","BK0070","BK0187","BK0209","BK0183","BK0250","002489","002675","002294","BK0214","002165","002272","BK0256","BK0260","BK0200","688602","BK0259","BK0120","BK0185","BK0010","000016","BK0028","BK0239","002640","BK0126","BK0196"],"gpt_icon":0},{"id":"2527946447","title":"【创新药概念反复活跃,一品红涨超10%续创历史新高】一品红涨超10%,股价续创历史新高,东诚药业涨停,悦康药业、科兴制药、智翔金泰、前沿生物、热景生物、百济神州等涨幅靠前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527946447","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527946447?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:55","pubTimestamp":1744595733,"startTime":"0","endTime":"0","summary":"一品红涨超10%,股价续创历史新高,东诚药业涨停,悦康药业、科兴制药、智翔金泰、前沿生物、热景生物、百济神州等涨幅靠前。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/14095549514272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688658","002675","LU1969619763.USD","BK4139","159992","BK1500","06160","ONC","BK1161","688068","688235","LU0588546209.SGD","BK0239","BK1588","06978","LU2328871848.SGD","BK1574","688443","688136","688221","BK1583","300723","LU0307460666.USD"],"gpt_icon":0},{"id":"2517487145","title":"东诚药业:公司在追求经济效益的同时注重环境保护和节能降耗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517487145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517487145?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:50","pubTimestamp":1741351818,"startTime":"0","endTime":"0","summary":"证券之星消息,东诚药业(002675)03月07日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,我是一名公民,想请问贵公司在生产活动中,是否采取过一些相关措施来减少空气污染呢?希望贵公司能与我们一起提升空气质量,建设美好家园。东诚药业回复:您好,公司在追求经济效益的同时注重环境保护和节能降耗,把建设资源节约型和环境友好型企业作为可持续发展战略的重要内容。感谢您的关注!以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700042357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2517145921","title":"原料药拖累业绩 东诚药业转向核药","url":"https://stock-news.laohu8.com/highlight/detail?id=2517145921","media":"媒体滚动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517145921?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:46","pubTimestamp":1741283160,"startTime":"0","endTime":"0","summary":"业绩下滑背后,东诚药业传统原料药业务受降价影响销售收入出现明显下滑。从公司业务构成看,原料药业务为东诚药业第一大营收来源,不过占比正逐年降低,2024年已掉到50%以下。随着原料药营收占比下降,东诚药业押注多年的核药业务占比提升,也是公司目前正大力发展的方向。3月5日,东诚药业召开2024年业绩说明会,针对投资者重点关注的公司业绩下滑、新产品研发等问题一一进行回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-03-07/doc-inentxuv7506518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2517199705","title":"东诚药业:3月5日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2517199705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517199705?lang=zh_cn&edition=full","pubTime":"2025-03-05 19:01","pubTimestamp":1741172489,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年3月5日东诚药业发布公告称公司于2025年3月5日召开业绩说明会。主要原因是原料药中肝素钠产品的销售价格大幅下降,尽管销量有所增长,但价格的下降导致整体收入下滑;2024 年公司归母净利润为 1.8 亿元,同比下降 12%,主要受到原料药销售价格下滑、研发投入大幅增加和融资带来的财务费用增加三方面影响。东诚药业主营业务:主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500033985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2514835508","title":"东诚药业(002675)2024年年报简析:净利润减12.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514835508?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:02","pubTimestamp":1740693733,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期东诚药业发布2024年年报。根据财报显示,东诚药业净利润减12.35%。截至本报告期末,公司营业总收入28.69亿元,同比下降12.42%,归母净利润1.84亿元,同比下降12.35%。按单季度数据看,第四季度营业总收入7.07亿元,同比上升2.35%,第四季度归母净利润1695.76万元,同比上升122.29%。持有东诚药业最多的基金为银河医药混合A,目前规模为4.81亿元,最新净值0.5116,较上一交易日上涨0.47%,近一年上涨4.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022800005242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675"],"gpt_icon":0},{"id":"2514878489","title":"东诚药业(002675)1月31日股东户数2.47万户,较上期减少2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514878489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514878489?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:11","pubTimestamp":1740647497,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东诚药业披露,截至2025年1月31日公司股东户数为2.47万户,较12月31日减少528.0户,减幅为2.1%。在化学制药行业个股中,东诚药业股东户数低于行业平均水平,截至1月31日,化学制药行业平均股东户数为3.09万户。从股价来看,2024年12月31日至2025年1月31日,东诚药业区间涨幅为3.76%,在此期间股东户数减少528.0户,减幅为2.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700029512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2514828676","title":"东诚药业:拟使用不超4亿元闲置自有资金购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2514828676","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514828676?lang=zh_cn&edition=full","pubTime":"2025-02-27 15:10","pubTimestamp":1740640202,"startTime":"0","endTime":"0","summary":"中国财富通2月27日 - 东诚药业(002675)公告称,2月26日,公司第六届董事会第九次会议和第六届监事会第七次会议审议通过了《关于使用闲置自有资金购买理财产品的议案》,同意公司及子公司使用自有资金不超过人民币4亿元购买理财产品。在上述额度内,资金可以滚动使用。该事项尚需提请公司股东大会审议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=G0o97otA9fM%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2514863503","title":"图解东诚药业年报:第四季度单季净利润同比增122.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514863503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514863503?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:11","pubTimestamp":1740589886,"startTime":"0","endTime":"0","summary":"证券之星消息,东诚药业2024年年报显示,公司主营收入28.69亿元,同比下降12.42%;归母净利润1.84亿元,同比下降12.35%;扣非净利润7927.4万元,同比下降62.69%;其中2024年第四季度,公司单季度主营收入7.07亿元,同比上升2.35%;单季度归母净利润1695.76万元,同比上升122.29%;单季度扣非净利润-7104.24万元,同比下降85.9%;负债率37.79%,投资收益-1398.5万元,财务费用7723.37万元,毛利率47.14%。筹资活动现金流出小计变动幅度为42.39%,原因:本期支付的租金同比增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700000375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675"],"gpt_icon":0},{"id":"2514836476","title":"东诚药业最新公告:2024年净利同比下降12.35% 拟10派0.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514836476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514836476?lang=zh_cn&edition=full","pubTime":"2025-02-26 19:49","pubTimestamp":1740570563,"startTime":"0","endTime":"0","summary":"东诚药业发布2024年度报告,2024年实现营业收入28.69亿元,同比下降12.42%;净利润1.84亿元,同比下降12.35%;基本每股收益0.22元。公司拟每10股派发现金红利0.3元(含税)。报告期内,公司原料药业务板块销售收入12.55亿元,同比下降25.17%,其中重点产品肝素类原料药产品实现营业收入8.44亿元,同比下降36.32%。肝素产品销售收入下降,主要原因为肝素钠销售价格下降。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022600036763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2514352838","title":"东诚药业(002675.SZ)发布2024年度业绩,净利润1.84亿元,下降12.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514352838","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514352838?lang=zh_cn&edition=full","pubTime":"2025-02-26 19:35","pubTimestamp":1740569700,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东诚药业 发布2024年年度报告,报告期内,公司实现营业收入28.69亿元,同比下降12.42%。实现归属于上市公司股东的净利润1.84亿元,同比下降12.35%。报告期内,核药业务板块销售收入10.12亿元,同比下降0.52%,其中重点产品18F-FDG实现营业收入4.21亿元,同比增长0.25%;云克注射液实现营业收入2.31亿元,同比下降5.48%;锝标记相关药物实现营业收入0.99亿元,同比下降0.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675"],"gpt_icon":0},{"id":"2512445798","title":"东诚药业(002675)2月19日主力资金净卖出748.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512445798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512445798?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:20","pubTimestamp":1740014431,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2025年2月19日收盘,东诚药业报收于13.65元,下跌1.8%,换手率0.89%,成交量6.62万手,成交额9114.29万元。近5日资金流向一览见下表:东诚药业融资融券信息显示,融资方面,当日融资买入756.73万元,融资偿还914.44万元,融资净偿还157.71万元。东诚药业主营业务:主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022000007894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2512715546","title":"【投融资动态】蓝纳成生物C轮融资,融资额1.5亿人民币,投资方为瑞力投资、东诚药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2512715546","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512715546?lang=zh_cn&edition=full","pubTime":"2025-02-18 19:31","pubTimestamp":1739878287,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP于2月13日公布的信息整理,烟台蓝纳成生物技术股份有限公司C轮融资,融资额1.5亿人民币,参与投资的机构包括瑞力投资,东诚药业,上海瀚宸铭企业管理合伙企业,投后估值29.5亿人民币。烟台蓝纳成生物技术股份有限公司成立于2021年,总部位于美丽的海滨城市烟台,子公司设立于新加坡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021800035376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2511566392","title":"东诚药业(002675.SZ)控股子公司蓝纳成拟实施增资扩股事项 充实资金储备","url":"https://stock-news.laohu8.com/highlight/detail?id=2511566392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511566392?lang=zh_cn&edition=full","pubTime":"2025-02-14 18:34","pubTimestamp":1739529265,"startTime":"0","endTime":"0","summary":"蓝纳成本次增资扩股完成后,注册资本变更为人民币8911.7903万元。公告称,蓝纳成此次增资扩股引入投资者有利于优化蓝纳成股权结构,充盈蓝纳成资金储备,利用商业化投资者资源,加快公司研发产品进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002675"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746562231124,"stockEarnings":[{"period":"1week","weight":-0.0093},{"period":"1month","weight":0.0976},{"period":"3month","weight":0.138},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.0701},{"period":"ytd","weight":0.2144}],"compareEarnings":[{"period":"1week","weight":0.009},{"period":"1month","weight":-0.0077},{"period":"3month","weight":0.0268},{"period":"6month","weight":-0.0445},{"period":"1year","weight":0.0558},{"period":"ytd","weight":-0.0106}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21576人(较上一季度减少12.51%)","perCapita":"34454股","listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":" 烟台东诚药业集团股份有限公司的主营业务是生化原料药、中西药制剂、放射性核素药物的研发、生产、销售。公司的主要产品是肝素钠原料药、硫酸软骨素、那屈肝素钙注射液、注射用氢化可的松琥珀酸钠、达肝素钠注射液、依诺肝素钠注射液、注射用绒促性素、注射用尿促性素。公司连续七年荣登“中国化药企业TOP100排行榜”,连续四年荣登“中国医药工业百强榜”,连续三年荣获“山东民营企业创新100强”,本年度公司首次荣获“2024中国化药研发实力100强”。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}